Skip to Main Content

Paper Details

Transplant outcomes after CPX-351 vs 7â¿¿+â¿¿3 in older adults with newly diagnosed high-risk and/or secondary AML.
Blood Adv
7
2022
Author NameAffiliation
Laura F NewellKnight Cancer Institute, Oregon Health & Science University
Tara L LinUniversity of Kansas Medical Center
  • 1 - 2

Datasets

Release 1.2